Vaxcyte, INC Form 4 insider transactions

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., was granted a performance stock option to purchase 11,900 shares of common stock on November 7, 2024.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., was granted a performance stock option to purchase 26,125 shares of the company's common stock.

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., was granted performance-based stock options and restricted stock units on November 7, 2024, subject to service and performance vesting conditions.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., received performance-based stock options and restricted stock units on November 7, 2024, as part of a company-wide grant.

Vaxcyte's CEO, Grant Pickering, reported the sale of common stock through a 10b5-1 trading plan and the grant of performance-based stock options and restricted stock units.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on November 1, 2024.

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., reports exercising stock options at prices of $5.35 and $20.93 on October 28, 2024.

Andrew Guggenhime, CFO of Vaxcyte, Inc., executed stock options and sold shares on October 25, 2024.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on October 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on September 18, 2024, according to a Form 4 filing with the SEC.

Director Teri Loxam exercised stock options and sold Vaxcyte shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan, while also transferring shares due to a divorce settlement.

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, CFO of Vaxcyte, Inc., reports disposition of shares to cover tax obligations upon vesting of restricted stock units.

Vaxcyte's CEO, Grant Pickering, reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold shares to cover tax obligations, according to a Form 4 filing.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reported the exercise of stock options and sale of common stock on September 3, 2024, according to a Form 4 filing with the SEC.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Andrew Guggenhime, CFO of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged trading plan.

Vaxcyte's Chief Operating Officer, Jim Wassil, sold a portion of his common stock holdings on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte CEO Grant Pickering sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte's CEO, Grant Pickering, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.